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Abstract
The intrahelical salt bridge between E/D3.49 and R3.50 within the E/DRY motif on helix 3 (H3) and the interhelical hydrogen
bonding between the E/DRY and residues on H6 are thought to be critical in stabilizing the class A G protein-coupled
receptors in their inactive state. Removal of these interactions is expected to generate constitutively active receptors. This
study examines how neutralization of E3.49/6.30 in the thromboxane prostanoid (TP) receptor alters ligand binding, basal, and
agonist-induced activity and investigates the molecular mechanisms of G protein activation. We demonstrate here that a
panel of full and partial agonists showed an increase in affinity and potency for E129V and E240V mutants. Yet, even
augmenting the sensitivity to detect constitutive activity (CA) with overexpression of the receptor or the G protein revealed
resistance to an increase in basal activity, while retaining fully the ability to cause agonist-induced signaling. However, direct
G protein activation measured through bioluminescence resonance energy transfer (BRET) indicates that these mutants
more efficiently communicate and/or activate their cognate G proteins. These results suggest the existence of additional
constrains governing the shift of TP receptor to its active state, together with an increase propensity of these mutants to
agonist-induced signaling, corroborating their definition as superactive mutants. The particular nature of the TP receptor as
somehow ‘‘resistant’’ to CA should be examined in the context of its pathophysiological role in the cardiovascular system.
Evolutionary forces may have favored regulation mechanisms leading to low basal activity and selected against more highly
active phenotypes.
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Introduction
The prostanoid receptor for thromboxane A2 (TXA2), called
TP, belongs to the Class A (rhodopsin family) of the superfamily of
heptahelical transmembrane receptors, commonly referred to as G
protein-coupled receptors (GPCRs), the most diverse form of
transmembrane signaling protein and the most privileged target of
marketed drugs. The TP receptor was originally purified from
human platelets and successively cloned from human placenta [1].
The G protein-coupling repertoire for TP receptors is rather
extensive. It is classically considered a Gq-coupled receptor
activating the PLCb – IP3/DAG – Ca
++/PKC signaling cascade,
based on the phylogenetic and experimental analysis [2,3].
However, it has been shown to couple also to Gs, Gi and G12/13
[1]. In humans, TP receptor exists in two isoforms sharing the first
328 amino acids, TPa (343 residues) and TPb (407 residues),
which is an alternative mRNA splicing variant with an extended
carboxyl terminus.
The TXA2/TP receptor system is of great pathophysiological
importance in the cardiovascular system. Indeed, TP receptor
activation produces platelet shape change and aggregation,
providing a positive stimulus for causing thrombus formation.
Furthermore, the equilibrium between platelet-derived TXA2 and
endothelial-derived prostacyclin represents the rationale for the
use of anti-thrombotic low-dose aspirin, but also the proposed
cause of cardiovascular side effects of COX-2 selective inhibitors
[4]. TP receptor expression and activity account for its involve-
ment in diseases based on endothelial dysfunction and prolifera-
tion such as atherosclerosis [5], and cancer [6]. In this context, TP
receptor function appears to be tightly regulated at gene and
protein level. Accordingly, the deleterious cardiovascular effects of
TPa could be limited by heterodimerization with the alternatively
spliced TPb [7,8] or the counteracting prostacyclin receptor IP
[9,10], which have been shown to regulate its trafficking and G
protein coupling.
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Many issues regarding GPCR function are still unclear despite a
number of (seventeen) GPCRs have been crystallized so far, from
rhodopsin to ß-adrenergic (ARs), muscarinic, and more recently
opioid receptors. A common feature thought to be important in
the process of activation of many class A GPCRs is the network of
interactions carried out between the charged R3.50 in the
conserved E/DRY motif at the end of helix 3 (H3) and the E6.30
in H6, the so called cytoplasmic ionic lock, and the E/D3.49 in the
intrahelical salt bridge. This network of interactions is observed in
all of the inactive rhodopsin crystal structures [11], in the
dopamine D3 receptor [12] and in a limited subset of A2A [13]
and b1-AR [14] structures, and has been implicated through
mutagenesis as a major factor stabilizing receptors in their inactive
conformation [15,16].
We previously showed that neutralization of R3.50 in the TP
receptor did not result in a constitutively active mutant (CAM), but
assigned Arg a dual role in participating in the reinforced
hydrogen bond network of the ionic lock and in direct binding
with the G protein [15,17]. As suggested by molecular dynamic
(MD) simulations of TP receptor [18], we formerly observed that
neutralization of E3.49 and E6.30 resulted in mutants characterized
by a maximum U46619 response larger than in wild-type (WT).
However, these mutants lacked any elevation of basal G-protein/
effector activity, a phenotype clearly different from the constitu-
tively active that we named superactive [19]. This contribution is
aimed to demonstrate that the observed phenotype is not a feature
restricted to a single agonist, but rather a fundamental character-
istic of the superactive mutants (SAMs), and that other hallmarks
of the active-like conformation are preserved defining a unique
pharmacological profile for these proteins. Crucial points were to
challenge the peculiar resistance of TP to a ligand-independent
activity and to gain information on the molecular mechanism
underlying increased agonist-induced activation and signaling
(superactivity).
Materials and Methods
Reagents
Cell-culture media, animal serum, antibiotics, other supple-
ments, Lipofectamine 2000, Opti-MEM I and molecular biology
reagents were purchased from Invitrogen (Carlsbad, CA). Inositol-
free Dulbecco’s modified Eagle’s medium (DMEM) was obtained
from ICN Pharmaceuticals Inc. (Costa Mesa, CA). Ultima Gold
was from PerkinElmer Life and Analytical Sciences (Boston, MA),
as were [5,6-3H]SQ29,548 and myo-[2-3H]inositol. U46619 ([1R-
[1a,4a,5b(Z),6a(1E,3S*)]]-7-[6-(3-hydroxy-1-octenyl)-2-oxabicyclo
[2.2.1]hept-5-yl]- 5-heptenoic acid), I-BOP ([1S-[1a,2a(Z),3b
(1E,3S*),4a]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-ox-
abicyclo[2.2.1]hept-2-yl]-5-heptenoic acid), 8-isoPGF2a (8-iso
Prostaglandin F2a), 8-isoPGE2 (8-iso Prostaglandin E2), PTA2
(Pinane TXA2 - 9a,11a-(dimethyl)methylene-15S-hydroxy-11a-
deoxy-11a-methylene-thromba-5Z,13E-dien-1-oic acid) and
SQ29,548 ([1S-[1a,2a(Z),3a,4a]]-7-[3-[[2-[(phenylamino)carbo-
nyl]-hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic
acid) were from Cayman Chemical (Ann Arbor, MI). Coelenter-
azine 400a (CLz400) and coelenterazine h were from Biotium
(Hayward, CA). Anion exchange resin AG 1X-8 (formate form,
200–400 mesh) and Lowry dye-binding protein reagents were
from Bio-Rad (Hercules, CA). All other reagents of the highest
purity were available from Sigma-Aldrich (St. Louis, MO).
Constructs
DNA constructs of TP receptor WT, E129V, and E240V were
previously obtained in our laboratory [17,19]. E129V/E240V
substitutions were introduced into the cDNA for human TPa
receptor using the same mutant oligonucleotides and method used
to obtain the single mutant receptors, as previously published [19]
and the identity of the double mutant was assessed by sequencing.
The cDNA encoding for the Gaq was purchased at Missouri S&T
cDNA Research Center (Rolla, MO, USA). The plasmids
encoding GFP10-Gc2 and Gb1 have been previously described
[20] and the expression vector for Gq proteins fused to Renilla
luciferase, that brings eight favor mutations (Gaq-Rluc8) cDNA is
described in Saulie`re et al., [21]. Ultrapure plasmids for cell
transfection were obtained using the QIAfilter Plasmid Kits by
Qiagen (Hilden, Germany).
Cell culture and transient transfections
HEK293 transfection host cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA). Cells
were routinely grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS, 2 mMglutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and 20 mM HEPES buffer
pH 7.4, at 37uC in a humidified atmosphere of 95% air and 5%
CO2. For transfection, cells were seeded onto tissue culture dishes
previously coated with 10 mg/ml poly-D-lysine, and transfected at
50–60% confluence with an optimized 2:1 Lipofectamine 2000/
DNA ratio following manufacturer’s instructions, as described
previously [19]. All assays were performed 48 hours after transfec-
tion. In cotransfection experiments with TP and Gaq, plasmids were
added in a 1:3 and 1:5 mg ratio, respectively.
Radioligand binding and total inositol phosphate assays
Receptor expression and functional activity were monitored
48 hours after transfection. Ligand binding characteristics were
determined on confluent adherent cells performing a mixed-type
protocol [22] with the specific receptor antagonist [3H]SQ29,548
(48 Ci/mmol) as previously described [17,19]. Heterologous
competition studies involved concentrations of the indicated
unlabeled ligands extending from 0.1 nM to 30 mM. After
30 min incubation at 25 uC, the reaction was stopped by
aspiration of the medium, cells were washed with ice-cold PBS
containing 0.2% (w/v) BSA and lysed in 0.5 N NaOH.
Radioactivity was measured by liquid scintillation counting.
Binding data were analyzed as described in Data and Statistical
Analysis. Quantification of the total labeled inositol phosphates
(IP) accumulation was performed using a conventional gravity flow
column chromatography, as described previously [17,19]. Briefly,
the day before the assay, cells were labeled with 0,5 mCi of [myo-
2-3H]inositol (17 Ci/mmol) for 18–20 hours in serum-free,
inositol-free DMEM containing 20 mM HEPES buffer, pH 7.4,
and 0.5% (w/v) Albumax I. The day of the assay, media was
replaced with serum-free, inositol-free DMEM containing 25 mM
LiCl and cells stimulated for 30 min with the indicated agonists.
After removal of the medium, cells were lysed with 10 mM formic
acid and lysates were applied onto an anion exchange AG 1X-8
column, formate form, 200–400 mesh. The total IP fraction was
then eluted with 2 M ammonium formate/formic acid buffer at
pH 5 and radioactivity determined by liquid scintillation counting.
Rescue experiments were performed essentially as above, except
for a 18 hours incubation step with 1 mMof SQ29,584 followed by
its removal by washing three times with ice-cold PBS containing
1 mM MgCl2 and 0.1 mM CaCl2 before starting the experiment.
Bioluminescent resonance energy transfer
HEK 293 cells were co-transfected with vectors expressing the
GFP10-Gc2, Gb1, Gaq-Rluc8 and WT or E129V mutant of TP
receptor to investigate direct G protein activation with an
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intramolecular bioluminescent resonance energy transfer (BRET2)
strategy. To avoid possible variations in the BRET signaling
resulting from fluctuation in the relative expression levels of the
energy donor and acceptor, we designed transfection conditions to
maintain constant GFP10 and Rluc8 expression and their ratios in
each experimental set. Total fluorescence and luminescence were
directly determined in an aliquot of the transfected cells using an
Infinite F500 microplate reader (Tecan, Milan, Italy) as previously
described [23]. WT and mutant TP receptor level of expression,
evaluated by binding experiments, were comparable in each
experimental set and constant among experiments. 48 hours after
transfection, cells were washed once with PBS, detached, and
resuspended in PBS+0.1% (w/v) glucose at room temperature.
Cells were then distributed (80 mg of proteins per well) into a 96-
well microplate (Wallac, Perkin Elmer, Monza, Italy) and
incubated in the presence or absence of increasing concentrations
of ligands for 2 min before the addition of the luciferase substrate
Coelenterazine 400a (5 mM; Biotium, Hayward, CA). BRET
signal between Rluc8 and GFP10 was measured immediately after
the addition of the Rluc substrate in the microplate reader. The
BRET signal was calculated as the ratio of the light emitted by
GFP10 (510–540 nm) over the light emitted by Rluc8 (370–
450 nm). The changes in BRET induced by the ligands were
expressed as O`agonist-induced BRETO´, obtained by subtracting
the BRET signal detected in the presence of PBS by the BRET
signal detected in the presence of the specific ligand.
Data and statistical analysis
All average results are presented as mean6S.E. When
indicated, ANOVA followed by post-hoc test for multiple
comparisons was performed. Data from radioligand binding were
evaluated by a nonlinear, least-squares curve-fitting procedure
using GraphPad Prism version 4, implemented with the n-ligand
m-binding site model, as described in the LIGAND computer
program [24]. Concentration-response curves were evaluated
using Prism 4, which use the four parameters logistic model as
described in the ALLFIT program [25]. Parameter errors are all
expressed in percentage coefficient of variation (%CV) and
calculated by simultaneous analysis of at least two different
independent experiments performed in duplicate or triplicate.
Parameter comparison has been performed on the base of the F
test for extra sum of square principle. All curves shown are
computer generated.
Results
Analysis of Wild Type and Mutant TP Receptors
Expression
Binding assays were performed with the specific antagonist
[3H]SQ29,548 in HEK293 cells transiently transfected with WT,
mutants of the human TPa receptor isoform, or vector alone.
Mock-transfected cells showed no binding to [3H]SQ29,548 (data
not shown). WT and mutant receptors were expressed at a level
sufficient to perform radioligand binding analysis, yet, to allow a
proper comparison of receptor response. Thus, transfection
conditions were adjusted to secure equivalent levels of receptor
expression for WT and mutants as previously described [8,17,19].
Computer-assisted analysis of binding data from WT receptor and
mutants revealed, as expected for neutral antagonists (see below),
monophasic binding curves fitting a single site model. Calculated
affinities for the WT and mutant receptors were in the nanomolar
range, as previously reported [17,19], while capacities ranged
approximately from 0.3 to 0.9 pmol/mg protein, a level compa-
rable to receptor expression in human platelets (Table 1). All the
experiments were conducted within this range of receptor
expression, if not specified differently.
Agonist-induced signaling and binding profile
We previously observed that the TXA2 stable analog U46619
stimulated total IP formation by E129V and E240V mutants with
a significant 10-fold lower EC50 and higher Emax than the WT
receptor [19]. To further expand these observations and assess if
these specific stimulation characteristics are also be found for other
agonists, providing stronger evidence for superactivity, agonist-
induced concentration-response curves were obtained for a series
of TP agonists, such as the full agonist I-BOP and the partial
agonists isoprostanes, 8-iso-PGF2a and 8-isoPGE2 in E129V,
assumed as a standard example of SAM. Computer assisted
analysis showed that the EC50s of the agonists for E129V were
significantly 10 to 20 fold leftward shifted (p,0.01) with respect to
that of the WT (Figure 1 and Table 2). In addition, the full agonist
I-BOP showed a greater efficacy in activating the E129V SAM
compared to the WT TP receptor in agreement with data from
U46619, whereas the intrinsic activity of the two partial agonists 8-
iso-PGF2a and 8-isoPGE2 was augmented, with maximum
efficacies not statistically different from those of the full agonists
(Figure 1B and Table 2). We also previously demonstrated that the
heterologous competition curves of the unlabeled agonist U46619
vs. [3H]-SQ29,548 revealed a leftward shift for the E129V mutant
curve compared to WT receptor [19]. Thus, binding of the panel
of agonists was performed to assess whether the mutation modified
their binding profile. Figure 2 clearly shows that the entire panel of
agonists, including the two partial agonists, reveals a significant
(p,0.01) increase in affinity up to one order of magnitude
(Table 3), confirming a unique binding profile for the E129V SAM
with respect to different structural and pharmacodynamic classes
of compounds. These data, therefore, suggest a change in the
receptor conformation, as identified by an increase in agonist
affinities, but similar conserved folding and quaternary structure,
as identified by unchanged antagonist affinity.
Table 1. Binding affinities of [3H]SQ29,548 in HEK293 cells
transiently expressing the WT or mutant human TP receptors.
Receptor Gaqa Kd, nM±%CV
Bmax, pmol/mg
prot±%CV
WT - 11.25620 0.44632
WT 3x 15.50611 0.90646
WT 5x 8.85612 0.95639
E129V - 9.25619 0.53616
E129V 3x 8.45629 0.38621
E129V 5x 7.98628 0.39630
E240V - 10.03615 0.97631
E240V 3x 7.53633 0.65652
E240V 5x 8.50653 0.49634
E129/240V - 9.06652b 0.04668 b
Binding affinities and capacities were obtained by simultaneous analysis of at
least 3 independent mixed-type experiments each performed in duplicates,
analyzed with GraphPad Prism implemented with the LIGAND model (see Data
and statistical analysis).
aIn cotransfection experiments, TP and Gaq plasmids were added in a 1:3 (3x)
and 1:5 (5x) ratio (see methods for details).
bParameters refer to E129/240V double mutant before SQ29,548 rescue.
doi:10.1371/journal.pone.0060475.t001
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Analysis of Basal Activity and U46619-induced response
in the presence of overexpression of Gaq
A key feature that we previously observed in SAMs of TP
receptor is that, albeit adopting an active-like conformation, they
lack the increase in basal activity [15,19]. Since theoretically it can
be anticipated that the raise in G protein concentration should
shift the R-R* equilibrium to favor the formation of the active R*,
the basal activities of WT and SAM TP receptors were assayed by
analyzing their ability to activate production of total IP in the
absence of agonist stimulation, but in the presence of overexpres-
sion of Gaq. Here we confirm that, in the absence of Gq
overexpression none of the TP receptor mutants exhibited CA
when expressed at equal protein level (Fig. 3A, w/o Gq). In
addition, considering that the solely overexpression of Gq in the
absence of any TP receptor expression (mock, textured bars)
induced a dose-dependent increase of total IP production (43%
and 118% for -3 and 5-fold Gq respectively, Fig. 3A), we can
conclude that the enhance in IP accumulation is not driven by WT
TP receptor expression (white vs. textured bars). E129V and
E240V yielded only a modest 2-fold increase in agonist-
independent activity (Figure 3A, solid gray and black bars vs.
textured bars). Interestingly, U46619-induced total IP production
is amplified in the presence of increasing amount of Gq protein
(Figure 3B) and its potency is augmented (data not shown), as it
would be expected by an increased availability of signaling
proteins. Yet, in the latter condition the agonist-induced activation
of SAM receptors showed a fold-increase in total IP production
that is comparable to the WT (Figure 3C). This behavior is not
typical for CAM receptors, which are usually strongly impaired in
agonist-induced stimulation as their basal activity increase and get
close to the maximal response allowed by the system [26,27].
Performing transfections with increasing DNA concentrations to
augment receptor expression in conditions of Gaq overexpression
(to avoid G protein depletion) there was a slight but not significant
increase in basal activity for the SAM with respect to the WT
receptor (Figure 3D).
As predicted by the ternary complex model, the affinity for the
labeled [3H]-SQ29,548 did not show any variation between WT
and SAMs in the presence of overexpression of Gaq with respect
to basal G protein expression (see Table 1).
Figure 1. Agonist-induced total IP accumulation in HEK293 cells transiently expressing equal amounts of the WT (A) or E129V
mutant (B) of human TP receptor. Total IP accumulation was measured after incubation in the absence (basal) or presence of increasing
concentrations of the indicated agonists for 30 min. Data are expressed as dpm/well. Error bars represent mean6SE of at least three independent
experiments each performed in duplicates or triplicates (For the sake of clarity, in panel B, error bar direction of U46619 and I-BOP data is above and
below, respectively). Curves are computer generated from the simultaneous analysis of at least three independent experiments. Values for EC50 and
significant differences from WT are shown in Table 2.
doi:10.1371/journal.pone.0060475.g001
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Pharmacological characterization of the E129V/E240V
double mutant
To further characterize the behavior of a receptor bearing
multiple mutations possibly affecting its conformation in a broader
and unexplored way, we constructed the E129V/E240V double
mutant. Expression levels of E129V/E240V were negligible
making impossible to perform significant analysis of functional
activity, despite similar antagonist affinity to WT (Table 1). We
Figure 2. Agonist binding studies in HEK293 cells transiently expressing the WT (A) or E129V mutant (B) of human TP receptor. For
each construct, cold U46619, I-BOP, 8-isoPGF2a or 8-isoPGE2 was used in competition for 1 nM [
3H]SQ29,548. Mixed type curves and heterologous
competition curves were performed at 25uC with 30 min incubation. Binding is expressed as the ratio of bound ligand concentration to total ligand
concentration (B/T, dimensionless) versus the logarithm of total unlabeled ligand concentration (Log T). Non-specific binding was calculated by
computer as one of the unknown parameters of the model and was always ,10% of total binding. Curves are computer generated from the
simultaneous analysis of several independent mixed-type and heterologous competition experiments, each in duplicate. Values for Ki and significant
differences from WT are shown in Table 3.
doi:10.1371/journal.pone.0060475.g002
Table 2. Total IP dose-response parameters for different agonists in HEK293 cells transiently expressing the WT or the E129V TP
receptor.
WT E129V
Agonist EC50, nM±%CV Emax, dpm/well±%CV EC50, nM±%CV Emax, dpm/wel±%CV Activity ratio
a
U46619 98.68670 1237468 4.47636** 1811565 22.1
I-BOP 25.11665 13099614 2.99656** 1715668 8.4
8-isoPGE2 1155672 5087621 95.93660** 1220165 12.0
8-isoPGF2a 3999668 6744642 493.1653** 1528767 8.1
Values of EC50 and Emax were obtained by simultaneous analysis with GraphPad Prism (see Data and statistical analysis) of at least three independent experiments each
performed in duplicates.
aActivity ratio was calculated as the ratio of the EC50 for the WT TP receptor over the EC50 of the E129V mutant.
**p,0.01 vs. WT.
doi:10.1371/journal.pone.0060475.t002
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therefore explored the possibility that the double mutant might be
retained and not sufficiently available for signal transduction by
performing functional rescue experiments exposing cells to 1 mM
SQ29,548 for 18 hours [28]. Analysis of agonist-induced signal
transduction was performed after removal of SQ29,548 by
repeating washing (see methods). Figure 4A clearly shows that
SQ29,548 is able to rescue double mutant receptor functional
activity, albeit not completely compared to the WT or single
mutant phenotypes (see Figure 1). The general features of this
mutant are consistent with those observed for each single SAM.
Analysis of basal activity and of the concentration-response curve
of U46619 revealed the absence of CA (compare with Figure 3A)
and an EC50 value of 1.66 nM633%CV consistent with those
previously obtained for SAMs [19].
Pharmacodynamic analysis of TP antagonists in the
presence of Gaq overexpression
SQ29,548 behaved as a pure antagonist in either the absence or
presence of Gaq overexpression with respect to WT and E129V
mutant (Figure 5A). Of interest, the purported antagonist pinane-
TXA2 (PTA2) [29] behaved as a very weak partial agonist with
respect to WT TP receptor (Emax 5856 dpm/well614%CV), but
as a much stronger agonist with respect to E129V SAM (Emax
19423 dpm/well62%CV) as well as in conditions of Gaq
overexpression (EC50 1447 nM667%CV and Emax 19670 dpm/
well615%CV for WT; EC50 747 nM676%CV; Emax
26642 dpm/well65%CV for E129V) (Figure 5B). Similar Ki has
also been obtained in heterologous competition experiments for
PTA2 between WT and E129V (Ki 12140 nM639%CV and
4836 nM631%CV, respectively). Overall, these observations
suggest that the SAM has the propensity to assume a conformation
more prone to be activated by a weak agonist, but despite the
availability of an excess of signaling molecules, i.e. Gaq proteins in
this case, they are ‘‘resistant’’ to CA.
Table 3. Affinities of the agonists for the binding site of the
receptor labelled by [3H]SQ29,548 in HEK293 cells transiently
expressing the WT or the mutant human TP receptors.
Agonist WT Ki, nM±%CV
E129V Ki,
nM±%CV Affinity ratioa
U46619 169.90613 16.32618** 10.4
I-BOP 24.27618 3.90621** 6.2
8-isoPGE2 2916615 547.662** 5.3
8-isoPGF2a 12930619 2908611** 4.4
Ki values were obtained by simultaneous analysis of at least 3 independent
competition experiments analyzed with GraphPad Prism implemented with the
LIGAND model (see Data and statistical analysis).
aAffinity ratio was calculated as the ratio of the Ki for the WT TP receptor over
the Ki of the E129V mutant.
**p,0.01 vs. WT.
doi:10.1371/journal.pone.0060475.t003
Figure 3. Analysis of basal and agonist induced total IP accumulation in HEK293 cells transiently expressing the WT or SAM
mutants of human TP receptor in the absence and presence of Gaq overexpression. TP and Gaq plasmids were added in a 1:3 (3x) and 1:5
ratio (5x), respectively. A. Total IP accumulation in basal conditions. B. Total IP accumulation induced by 30 min stimulation with 1 mM U46619. C. Fold
increase over basal of total IP accumulation. D. Basal activity for WT and SAMs with increasing receptor expression in pmol/mg protein. Data are
expressed as dpm/well. Error bars represent mean6SE of at least three independent experiments each performed in duplicates or triplicates.
doi:10.1371/journal.pone.0060475.g003
Fine Tuning of TP Superactive Conformation
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Direct G protein activation
To challenge predictions from MD simulation suggesting a
more ‘‘efficient’’ coupling of SAMs with their cognate G protein
compared to WT receptor [19], we performed a direct measure of
G protein activation by using an intramolecular BRET2 strategy in
which Renilla reniformis luciferase 8 (Rluc8) [30] is the energy
donor and GFP10 is the energy acceptor. This recorded real time
conformational changes between the a and the bc subunits within
the Gq protein, where a decrease of the BRET signal provoked by
agonist-induced receptor activation is indicative of a conforma-
tional reorganization leading the Ga-Gbc interface to open,
reflects the initial event of Gq protein activation [20,23]
(Figure 6A).
After setting the optimal transfection conditions (Figure 6B) to
avoid possible variations in the BRET signal resulting from
fluctuations in the relative expression levels of the energy donor,
evaluated as the total Gaq-Rluc8 luciferase emission, and acceptor
and to assure the same level of basal BRET signal for WT and
SAMs (1:1:1.25 a:b:c ratio), concentration-response curves of the
stable agonist U46619, I-BOP and of the isoprostanes 8-iso-PGF2a
and 8-isoPGE2 have been obtained in HEK293 cells expressing
equal amount of WT and E129V receptors. As it is clear from
Figure 6C, U46619 and I-BOP curves obtained with the E129V
mutant show an increased efficacy and more than one order of
magnitude leftward shift with respect to the curves obtained with
the WT TP receptor. Similarly, isoprostanes show an increase in
potency and intrinsic activity when activating the E129V mutant.
Analysis of the data indicated EC50 values for E129V and WT that
are in good agreement with those obtained from the analysis of
total IP dose-response curves (compare Table 2 and 4). Statistical
comparison of potencies and efficacies provided a significant
difference between parameters obtained with WT and E129V,
thus demonstrating a more ‘‘efficient’’ G protein activation by
E129V mutant protein (Table 4).
Discussion
In many GPCRs, the intrahelical salt bridge between E/D3.49
and R3.50 within the E/DRY motif on H3 and the interhelical
hydrogen bonding between the R3.50 and residues on H6 are
thought to form a network that is disrupted during receptor
Figure 4. Functional analysis of basal and agonist induced total IP accumulation in HEK293 cells transiently expressing the double
mutant E129V/E240V of human TP receptor without and following rescue with 1 mM SQ29,548 for 18 h. A. Total IP accumulation in
basal condition and following 30 min stimulation with 1 mM U46619. B. Concentration-response curves of U46619. Error bars represent mean6SE of
at least two independent experiments each performed in duplicates.
doi:10.1371/journal.pone.0060475.g004
Fine Tuning of TP Superactive Conformation
PLOS ONE | www.plosone.org 7 March 2013 | Volume 8 | Issue 3 | e60475
activation, unlashing constraints imposed on the two helices [31].
These data have been more recently confirmed by several crystal
structures of activated opsin [32,33] or constitutively active
rhodopsin [34,35]. Mutations on both sides of this network were
shown to increase basal activity of a number of receptors,
including another prostanoid receptor, FP [36], yet not in all [15].
The extended ternary complex model (ETC) of interactions
among receptor, ligand, and G protein was first suggested by
pharmacological analysis of adrenoreceptor CAMs [37]. Several
features were predicted based on this model that make a
distinction between CAMs and WT receptors. These character-
istics include an increase in ligand-independent activity, an
increase in ligand affinity/potency that correlates with compound
pharmacodynamic (i.e., largest shifts for full agonists, no changes
for antagonists), and a systematic amplification of partial agonist
efficacy.
We previously observed that introduction of valine, one of the
most non-conservative mutation affecting the extent of CA [26], at
the E3.49 and E6.30 produced TP mutants characterized by
enhanced agonist potency/efficacy upon activation by the TXA2
stable analog U46619 with respect to both Gq and Gs coupling
[19]. These traits are indicative of a mutation-induced active-like
conformation, which however did not trigger ligand-independent
signaling in contrast with the ETC prediction. For this distinctive
phenotype, these mutants were named superactive mutants
(SAMs) in alternative to CAMs [19], as has been very recently
observed also for the bradykinin B2 receptor [38].
The current study examines how SAMs of the TP receptor alter
ligand-induced binding and signaling with respect to WT. Here we
demonstrate that the increase in agonist potency is not a feature of
a single agonist (U46619), but is shared by a panel of full and
partial agonists. This observation is important to rule out the
possibility that the effect observed might be ligand-specific [39],
but to emphasize an intrinsic characteristic of the mutant protein.
Furthermore, the partial agonist isoprostanes displayed an
increased intrinsic activity, behaving as full agonists, whereas the
purported antagonist PTA2 behaved as partial agonist. Interest-
ingly, also the affinities of all the agonists were increased in ligand-
binding studies performed with the E129V mutant. All together,
these results strongly indicate that these mutated proteins adopt a
particular conformation indicative of a superactive state, which is
recognized by different full and partial agonists, and that identifies
a unique pharmacological profile. Of notice, the unaltered binding
characteristics of the neutral antagonist SQ29,548 suggest that the
folding and the overall conformation of SAM was not grossly
perturbed by the mutations. As expected, antagonist potencies
calculated in functional studies are only apparently reduced, due
to an increase in agonist potency.
Figure 5. Pharmacodynamic analysis of antagonists SQ29,548 and PTA2 in functional assay. Total IP accumulation in HEK293 cells
transiently expressing the WT or E129V mutant of human TP receptor was assayed in the absence and presence of Gaq overexpression at increasing
concentrations of the antagonists for 30 min. TP and Gaq plasmids were added in a 1:5 (5x) ratio. Data are expressed as dpm/well. Error bars
represent mean6SE of at least three independent experiments each performed in duplicates or triplicates. Curves are computer generated from the
simultaneous analysis of several independent experiments.
doi:10.1371/journal.pone.0060475.g005
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The sensitivity with which CA is detected is influenced by the
level of expression of receptor and G protein and the relative
stoichiometry to each other. Therefore, we studied whether rising
receptor or Gaq protein levels might boost ligand-independent
activity of WT and SAMs. Our data clearly demonstrate that basal
activity of WT TP receptor is neither affected by amplification of
receptor expression, nor of its cognate G protein. A modest
increase in CA of E129V and E240V SAMs can be observed only
Figure 6. BRET2 measurement of Gaqb1c2 complex activation in HEK293 living cells expressing equal amounts of the WT of human
TP receptor or its E129V mutant. A. BRET2 was measured between the donor Rluc8 and the acceptor GFP10 introduced at the residue 97 of the
Gaq subunit and the N-terminal domain of the Gc2 subunit, respectively. Agonist-induced coupling of TP receptor and Gq protein distances Gaq-
Rluc8 and GFP10-Gc2 giving rise to a decrease in the BRET signal. B. Protein expression levels of the constructs used for BRET experiments were set to
be constant and able to assure the same level of basal BRET ratio in the presence of WT and E129V mutant of the human TP receptors. Total Gaq-
Rluc8 luminescence was evaluated in HEK293 cells co-expressing Gaq-Rluc8 together with GFP
10-Gc2 and Gb1 in the presence of WT or E129V mutant
of the human TP receptor measuring the light emission in aliquots of the transfected cells incubated with 5 mM coelenterazine for 8 min. In the same
cells stimulated with PBS, basal BRET ratio was calculated as the ratio of the light emitted by GFP10 (510–540 nm) over the light emitted by Rluc8
(370–450 nm). C. BRET was measured in HEK293 cells co-expressing Gaq-Rluc8 together with GFP
10-Gc2 and Gb1 in the presence of WT (left) or E129V
(right) mutant of the human TP receptor and stimulated with increasing concentrations of the indicated full and partial agonists. Results are the
differences in the BRET signal measured in the presence and the absence of agonists, and are expressed as the mean value6SE of at least two
independent determinations.
doi:10.1371/journal.pone.0060475.g006
Table 4. BRET concentration-response parameters for different agonists in HEK293 cells transiently expressing the WT or the
E129V TP receptor.
WT E129V
Agonist EC50, nM±%CV Emax,±%CV EC50, nM±%CV Emax, dpm/well±%CV Activity ratioa
U46619 345.4614 20.0763 4.53625** 20.1164 76
I-BOP 13.01627 20.0765 3.96622** 20.1264 3.3
8-isoPGE2 1983672 20.02642 484.8646* 20.0868 4.1
8-isoPGF2a 3936648 20.0569 404.1631** 20.1264 9.7
Values of EC50 and Emax were obtained by simultaneous analysis with GraphPad Prism (see Data and statistical analysis) of at least two independent experiments each
performed in duplicates.
aActivity ratio was calculated as the ratio of the EC50 for the WT TP receptor over the EC50 of the E129V mutant.
*p,0.05, ** p,0.01 vs. WT.
doi:10.1371/journal.pone.0060475.t004
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after a substantial overexpression of Gaq, but not of Gaq and
receptor. While this behavior is rather predictable due to the
presence of an increased availability of signaling molecules (as
demonstrated by the increase in basal IP production in cells
transfected solely with Gaq), it really seems of little physiological
importance considering that both SAMs retain fully their ability to
cause agonist-induced signaling, something largely impaired in a
CAM. Thus, we have separated two fundamental aspects of
receptor function, basal and agonist-induced activity, supporting
the notion that the active receptor conformation induced by
agonists might be substantially different from that caused by
constitutive activation [39,40].
To test the hypothesis that CA might has gone unrecognized in
SAMs bearing a single amino acid mutation, we have also
generated and tested the double mutant E129V/E240V. Our data
reveal that without rescued cell surface expression of TP double
mutant, the cells lack the ability to generate IP in response to
U46619, indicating that the double mutant protein is somewhat
misrouted. However, restoring receptor to function again did not
reveal any increase in basal activity, yet showed potency similar to
that of E129V and E240V single SAMs. Therefore, we can
conclude that TP receptor basal activity is not or only marginally
affected by disruption of the extended network involving the
conserved ERY motif.
Of notice, despite the presence of residues capable of forming
the interhelical ionic lock, this interaction has not been found in
the majority of the GPCR crystal structures resolved so far
(regardless if they have been obtained in the presence of
antagonists or inverse agonists), with the exception of rhodopsin
[11], D3 receptors [12] and, to a limited subset of antagonist-
bound A2A [13] and b1-AR [14] structures. Nevertheless, this
interaction may still exist in the native receptors, as long time scale
MD simulations performed on the b2-AR [41,42], b1-AR [43] and
A2AR [44] show that the ionic lock reforms and breaks, suggesting
existence of equilibrium states characterized by the presence and
the absence of the lock that might reflect different requirements for
a basal activity in a physiological context. Therefore, receptors
might simply have a different propensity to form this interhelical
contact in the contest of the conformational plasticity character-
istic of GPCRs, which might explain the agonist-independent
activation observed for some of them. Interestingly, rhodopsin
[45], D3 [46] as well as the TP receptor have no or very low basal
CA, at variance with what has been reported for the b2-AR (even
bound to the inverse agonist carazolol [47]), b1-AR and A2A
[27,48,49].
In addition, Vogel and colleagues have demonstrated that
neutralization of the intrahelical salt bridge of rhodopsin is
considerably more critical for shifting the photoproduct equilib-
rium to an active-like conformation than the disruption of the
interhelical bonding between R3.50 and E6.30 [16]. This salt bridge
is indeed present in rhodopsin [11], D3 [12] and b2-AR [47,50]
bound to an antagonist or inverse agonist, and broken in both
opsin [32] and b2-AR [51] active structures. However, while
mutational studies on the E/D3.49 of opsin [45,52] or D3 receptor
[46] indicate only a partial or no increase in basal activity, the
same mutation in the b2-AR clearly produce a CAM [53]. Because
our data indicate that neither disruption of the intrahelical, nor of
the interhelical (or both) interaction(s) affect TP basal activity, we
might conclude that disruption of this network might be necessary
but not sufficient to achieve full receptor activation. Indeed, the
crystallographic structures of opsin [33] or even b2-AR [54] in
their G protein-interacting conformation show significant rear-
rangement of the transmembrane regions beyond the disruption of
the entire E/DRY network, suggesting that its neutralization
might be only one of multiple constraints that must be ‘‘unlashed’’
to achieve full receptor activation. Indeed, similar behavior has
been observed for other GPCRs [15], thus it seems conceivable
that some receptors have developed a large activation energy
barrier, while others might have a low energy barrier between the
R and R* states leading, in the latter case, to a relevant basal
activity [55].
We might speculate here that the increased affinity for full and
partial agonists demonstrated by our SAMs might be due to an
allosteric effect of the mutations at the agonist binding site,
independent of G protein coupling. Alternatively, the mutation
might shift the equilibrium toward one of the receptor species
theorized by the Cubic Ternary Complex model of Weiss and
colleagues, characterized by an increased ability to bind, but not
activate G proteins [56]. Indeed, the release of R3.50 from the
wrapped conformation in the ground state might allow the binding
of the Ga protein in a position previously occupied by H6
[32,33,34,35]. These findings are consistent with the loss of
agonist-induced signaling/G protein coupling observed upon
mutation of R3.50 for TP [17] as well as for a number of other
class A GPCRs [15], including rhodopsin [45,57] and dopamine
D3 receptor [46], just to limit to those that have been crystallized.
Furthermore, MD simulations of TP SAMs in complex with
heterotrimeric Gq revealed a better predisposition of R
3.50 to
perform connections at the receptor-G protein interface, as
demonstrated by a larger solvent accessible surface (SAS) area in
the cytosolic regions of the E129V mutant, compared to the WT
[19]. Thus, the effects of E3.49 mutation on the structural features
of TP is suggestive of an increased efficiency in G protein coupling.
This prediction has been challenged in vitro by performing a
BRET2-based assay to measure early activation of Gq protein
reflecting events close to the receptor and therefore not subjected
to signaling amplification, feedback and cross regulation from
different effector systems that may complicate interpretation of the
results. Monitoring BRET signal variations resulting from
structural rearrangements within the heterotrimeric Gaq and bc
protein in real time in living cells, we observed a significant
leftward shift of the BRET concentration-response curves (aug-
mented potency) and a larger decrease in BRET signal (augment-
ed efficacy) in the E129V dose-response curves for all the agonists
tested. In addition, for both the full agonist U46619 and the partial
agonist 8-iso-PGF2a the leftward shift between WT and E129V
mutant is larger in BRET signal (potency ratio of 76 and 9.7,
respectively. See Table 4) than in binding affinities (Ki ratio of 10
and 4.4, respectively. See Table 3), between WT and E129V
mutant. Overall, these observations may be interpreted as a
magnification of the ‘‘efficiency’’ with which SAM directly
promotes agonist-induced G protein activation. This, in turn,
can be the result of an increased receptor-G protein interaction
due to an enhanced G protein affinity for the receptor, or,
alternatively, to an increase in the rate of GDP/GTP exchange. In
either case, this effect should be ascribed to a change in the
receptor conformation of the SAMs.
Conclusions
Collectively, pharmacological data lead us to show not only that
non-conservative substitution of E3.49 and E6.30 TP results in
mutants characterized by higher affinity/potency for different
agonists, and increased intrinsic activity for partial agonists, but
also that SAMs are more efficient in G protein coupling and
activation. However, the low intrinsic basal activity of the TP
relative to that of other GPCRs, indicates that the equilibrium
between R and R* in TP strongly favors the inactive form. The
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failure of TP to be constitutively activated upon mutations in the
hydrogen bond network indicates that its disruption is not the only
structural feature required to activate the G protein, but rather
that additional mechanism(s) govern the R-R* transition, playing
variable roles in different GPCRs. In this light, and considering the
TXA2/TP receptor relevance in the pathophysiology of the
cardiovascular system, evolutionary forces may have favored
regulatory mechanisms leading to low basal activity and selected
against more highly active phenotypes.
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